Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 5 Adjusted absolute efficacy for biologic DMARDS + MTX at 24/26 and 48/54 weeks

From: Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis

Treatments relative to effect Absolute HAQ CFB
at 24/26 weeks
(95% CrL)*
Absolute HAQ CFB
at 48/54 weeks
(95% CrL)**
Proportion (%) of patients with ACR-50
at 24/26 weeks
(95% CrL) *
Proportion (%) of patients with ACR-50
at 48/54 weeks
(95% CrL)**
Proportion (%) of patients with DAS28 < 2.6
at 24/26 weeks
(95% CrL)*
Proportion (%) of patients with DAS28 < 2.6
at 48/54 weeks
(95% CrL)*
Placebo + MTX -0.29
(-0.31; -0.26)
-0.29
(-0.34; -0.24)
11.9%
(9.7%; 14.0%)
12.5%
(9.4%; 15.5%)
2.6%
(1.4%; 4.1%)
7.0%
(4.7%; 9.8%)
Adalimumab + MTX -0.61
(-0.77; -0.46)
-0.63
(-0.74; -0.51)
53.5%
(28.0%; 77.9%)
49.5%
(35.9%; 63.5%)
  
Certolizumab Pegol + MTX -0.67
(-0.82; -0.53)
-0.71
(-0.81; -0.61)
57.3%
(31.2%; 79.9%)
51.7%
(38.1%; 66.1%)
33.4%
(4.4%; 90.0%)
 
Etanercept + MTX -0.56
(-0.75; -0.38)
-0.63
(-0.87; -0.39)
30.7%
(15.6%; 65.2%)
43.2%
(31.8%; 54.9%)
6.9%
(1.0; 31.5%)
18.7%
(1.8%; 73.3%)
Golimumab + MTX -0.63
(-0.86; -0.39)
  34.6%
(9.7%; 69.2%)
  9.6%
(1.4%; 42.4%)
 
Infliximab + MTX -0.48
(-0.62; -0.33)
-0.48
(-0.59; -0.36)
26.0%
(6.6%; 57.4%)
28.1%
(19.4%; 38.3%)
12.6%
(1.9%; 53.3%)
28.8%
(1.9%; 89.5%)
Rituximab + MTX -0.49
(-0.68; -0.31)
-0.59
(-0.91; -0.27)
35.3%
(14.8%; 61.9%)
64.1%
(32.4%; 91.3%)
  
Tocilizumab + MTX -0.49
(-0.73; -0.26)
  47.5%
(16.1%; 78.6%)
  71.0%
(19.0%; 98.9%)
 
Abatacept + MTX -0.58
(-0.70; -0.46)
-0.58
(-0.66; -0.50)
31.7%
(15.9%; 50.6%)
35.4%
(27.3%; 43.3%)
11.3%
(3.7%; 28.8%)
40.2%
(10.4%; 80.3%)
  1. Note: For HAQ CFB, negative values indicate improvement.
  2. * Results based on a random effects model. ** Results based on a fixed effects model.
  3. 95% CrL, 95% credible limits